Translational scientist with 10+ years of experience bridging computational approaches with deep biological understanding to accelerate therapeutic development. I specialize in:

• Integrating multi-modal and multi-omic data (proteomics, transcriptomics, metabolomics)
• Developing and validating biomarkers for neurological conditions
• Applying advanced computational methods to complex biological problems
• Designing and implementing translational strategies for drug development

Currently focused on neurodegenerative diseases (ALS, Alzheimer's, Parkinson's/LBD, MS) with extensive experience leading cross-functional teams through innovative projects in collaboration with industry partners.

• Neurodegenerative Diseases: ALS, Alzheimer's, Parkinson's/LBD, Multiple Sclerosis
• Multi-Omic Integration: Network-based approaches, WGCNA, MEGENA
• Biomarker Discovery: Target engagement, patient stratification, disease progression
• Translational Strategy: Bridging preclinical findings to clinical applications
• Advanced Analytics: Machine learning, causal inference, longitudinal modeling

• Founder & Translational Scientist, Biostochastics, LLC
• Former Senior Research Scientist, Institute for Systems Biology
• Former Statistical Geneticist, Arivale
• Duncan Scholar in Human and Molecular Genetics, Baylor College of Medicine
• Postdoctoral Associate, Yale University School of Medicine
• PhD, Experimental Psychology, University of Connecticut
• PhD, Educational Psychology/Psychometrics, Moscow State University

I'm interested in collaborating on projects related to:

• Translational approaches in neurodegenerative disease
• Biomarker discovery and validation
• Multi-omic data integration methodologies
• Clinical trial design incorporating novel biomarkers
• Computational tools for drug development

Feel free to reach out if you're working in these areas or have ideas for potential collaboration.

For a complete list of my 65+ peer-reviewed publications, please visit my Google Scholar profile or connect with me on LinkedIn.

Select publications:

• Kornilov, S., Price, N., Gelinas, R., ... & Magis, A. (2024). Multi-Omic characterization of the effects of Ocrelizumab in patients with relapsing-remitting multiple sclerosis. Journal of the Neurological Sciences, 467, 123303
• Heath, L. Earls, J., Magis, A., Kornilov, S., ... Price, N. (2022). Manifestations of Alzheimer's disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90. Scientific Reports, 12(6117)
• Kornilov, S., Lucas, ... & Magis, A. (2020). Plasma levels of soluble ACE2 are associated with sex, Metabolic Syndrome, and its biomarkers in a large cohort, pointing to a possible mechanism for increased severity in COVID-19. Critical Care, 24, 452